-1752955251733.webp&w=3840&q=75)
2025 NOSCM | Non-metastatic and Metastatic Castration Resistant Prostate Cancer: Therapeutic Paradigm Shift
Overview
Dr. Petrylak discussed how CRPC treatment has evolved from docetaxel to PSMA-targeted therapies, boosting median survival to 26 months. PSMA PET scans aid early care. Pembrolizumab shows 60–70% response rates. Bispecifics (Genex, AMG 180) and PARP inhibitors help in select patients. FDA-approved Lutetium PSMA offers 19.25-month benefit.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Daniel Petrylak, MD
Date of Release
July 20th, 2025
-1755991286446.webp&w=3840&q=75)
-1755991157601.webp&w=3840&q=75)